Vancomycin: a history.
Donald P Levine
https://pubmed.ncbi.nlm.nih.gov/16323120/Actively Recruiting
Led by Children's Hospital of Philadelphia · Updated on 2025-09-19
52500
Participants Needed
4
Research Sites
N/A
Total Duration
Researchers are studying the use of vancomycin, a commonly prescribed antibiotic, in children admitted to Pediatric Intensive Care Units PICUs across five hospitals. The study aims to evaluate whether a multifaceted intervention can reduce unnecessary vancomycin use, which is important because overuse of this antibiotic can cause acute kidney injury in up to 25% of patients. The research also investigates infections that require vancomycin therapy and gathers feedback from clinicians to improve treatment practices. The intervention includes implementing clinical guidelines to advise when vancomycin should or should not be used, providing unit-level feedback on vancomycin use within and across the hospitals, and offering education to PICU clinicians and sepsis stakeholders. This intervention is adapted locally at each site. The study has two groups PICU clinicians and sepsis stakeholders who receive the intervention and education, and patients admitted to the PICUs whose medical records are reviewed to track antibiotic use and outcomes. Participants contribute by either receiving the intervention clinicians and stakeholders or having their medical records reviewed patients. Surveys and interviews are conducted with clinicians to understand the interventions impact. Data on vancomycin use and other outcomes like sepsis rates, mortality, length of stay, and readmissions are collected over baseline and up to five years post-intervention. Patient data are securely stored without personal identifiers. The study began in August 2023 and will continue until May 2026.
CONDITIONS
Reducing Empiric VAncomycin Use in Pediatric Suspected Sepsis
K
Kathleen Chiotos, MD, MSCE
K
Kai Inoki, MPH
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Children's Hospital of Philadelphia
Lead Sponsor
Children's Healthcare of Atlanta
Collaborating Sponsor
This table compares participation in this trial with other options available for this condition. The information is drawn from published research and the trial’s study details and is provided for educational purposes only.
| Factors | De-Implementation Strategy (Trial Approach) | Usual Empiric Antibiotic Prescribing (Current PICU Practice) |
|---|---|---|
| What it is | A multifaceted strategy delivered to PICU clinicians and sepsis stakeholders, including new clinical guidelines for vancomycin prescribing, group-level feedback on usage, and structured engagement to lower unnecessary vancomycin use. | Usual PICU practice, where vancomycin is often included in empiric antibiotic regimens for suspected sepsis without structured stewardship intervention or targeted group feedback on vancomycin usage. |
| Role in the trial | Main study intervention evaluated for its impact on vancomycin prescribing and sepsis-related outcomes in PICU settings. | Represents the established baseline for empiric vancomycin use in PICUs prior to structured stewardship or feedback programs. |
| Primary use or intent | Reduce clinically unnecessary empiric vancomycin prescribing for PICU sepsis patients by changing clinician behavior with feedback and updated guidelines. | Rapid empiric treatment of suspected sepsis, often including vancomycin for broad-spectrum antibiotic coverage, particularly to cover MRSA risk. |
| How it is given or performed | Clinicians and stakeholders receive targeted education, site-specific guidelines, routine reports on vancomycin use, surveys, and interviews to guide practice change and gather feedback. | Empiric antibiotics, including vancomycin, are ordered by clinicians based on individual judgment and local norms, without required feedback or centralized stewardship unless such programs are independently in use. |
| Evidence status | This trial is ongoing and will prospectively measure the impact of the de-implementation strategy on vancomycin use and sepsis outcomes in PICUs; published evidence on similar stewardship interventions in pediatrics show that feedback and education can reduce unnecessary antibiotic use. | Current usual care frequently leads to high rates of empiric vancomycin use in PICU sepsis patients, with studies showing substantial variability and frequent unnecessary exposure. Published surveys and reviews indicate opportunities for stewardship improvement. |
| Important limitations | Real-world effectiveness may vary by clinician engagement and local culture; results depend on sustainability of behavior change and robust measurement of both antibiotic use and patient-level outcomes. Long-term impact and generalizability remain to be established. | Usual empiric approaches can lead to overtreatment with antibiotics such as vancomycin, increasing risk for adverse events including nephrotoxicity and promoting resistance; lack of centralized stewardship can perpetuate non-evidence-based variation in prescribing. |
Disclaimer: This comparison is created with the help of artificial intelligence(AI) and may contain errors or missing information. It is not medical advice and does not mean one option is better or safer than another. Clinical trials are still being studied, and joining a trial is your choice. Please consult your healthcare professional before making any decisions.
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - Approximately 24 months
PICU clinicians and sepsis stakeholders receive clinical guidelines, unit-level feedback reports, and education aimed at reducing vancomycin use. Semi-structured interviews and surveys are conducted to assess implementation success and inform further intervention.
Surveys at baseline and 9 months post-implementation; semi-structured interviews during the intervention period
Duration - Up to 5 years
Medical record reviews are conducted to monitor vancomycin use, suspected and confirmed sepsis episodes, and other clinical outcomes among PICU patients during the baseline and post-intervention periods.
Data collection through electronic health records without requiring additional visits
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
NON_RANDOMIZED
Model
SINGLE_GROUP
Primary Purpose
OTHER
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Donald P Levine
https://pubmed.ncbi.nlm.nih.gov/16323120/Leonard A Mermel
https://pubmed.ncbi.nlm.nih.gov/32321614/Alison C Tribble, Brian R Lee, Kelly B Flett...
https://pubmed.ncbi.nlm.nih.gov/31942952/Barbara E Jones, Makoto M Jones, Benedikt Huttner...
https://pubmed.ncbi.nlm.nih.gov/26223995/Pyoeng Gyun Choe, Hei Lim Koo, Doran Yoon...
https://pubmed.ncbi.nlm.nih.gov/29661158/Yuta Aizawa, Junichi Suwa, Hiroshi Higuchi...
https://pubmed.ncbi.nlm.nih.gov/29688433/Theresa M Fiorito, Megan K Luther, Penelope H Dennehy...
https://pubmed.ncbi.nlm.nih.gov/29280786/Moacyr S Junior, Luci Correa, Alexandre R Marra...
https://pubmed.ncbi.nlm.nih.gov/17678541/Tamar F Barlam, Ellen Childs, Sarah A Zieminski...
https://pubmed.ncbi.nlm.nih.gov/32704510/Leonard A Mermel, Michael Allon, Emilio Bouza...
https://pubmed.ncbi.nlm.nih.gov/19489710/Children's Hospital of Philadelphia
Lead Sponsor
Children's Healthcare of Atlanta
Collaborating Sponsor